Merck to Ask FDA for Emergency Approval of Its New Antiviral Pill for COVID
The drug maker claims clinical trials of its new antiviral pill molnupiravir shows the drug halved the risk of hospitalization or death when given to high-risk people shortly after infection with COVID-19.
The drug maker claims clinical trials of its new antiviral pill molnupiravir shows the drug halved the risk of hospitalization or death when given to high-risk people shortly after infection with COVID-19.